Navigation Links
Increasing Proportion of Cardiovascular Disease Due to Diabetes,Over the Last 50 Years

LBI Communications Office
301-496-4236


'"/>




Page: 1 2 3

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
4. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
5. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
6. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
7. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
8. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
11. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
Post Your Comments:
(Date:10/8/2008)...NDRIA, Va., Oct. 8 /PRNewswire-USNewswire/ -- The ...ople die from HIV/AIDS in,sub-Saharan Africa. More...aharan Africa have already died of AIDS. The Found...g to ensure the dying and their families,find comp...e. FHSSA,s,innovative partnering initiative links ...
(Date:10/8/2008)...anolimumab Program to be Discontinued and Headcoun...ults of its Portfolio Review; Zanolimumab Program...e Number of Employee...- Genmab A/S (OMX: GEN),announced today that it is...D4(R)). In addition, as a result of a portfolio re...
(Date:10/8/2008)... France, Oct. 8 /- Vical Incorporated...nical data and new nonclinical data,demonstrating ...oadly,applicable in DNA- and protein-based infecti...ines. Alain P. Rolland, Pharm.D., Ph.D., Vical,s,S...present the data today,Wednesday, October 8, at t...
(Date:10/7/2008)...luates the efficacy of new device for detecting po...ng colonoscopy, ORLANDO, Fla., Oct. 7 /PRNewswire...nnual Scientific Meeting in Orlando (ACG 2008), re...nted results from a,multi-institutional clinical s...R) Retroscope(R), a new device that is designed to...
Breaking Medicine Technology:In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 2National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 3National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 4National Study Presented at ACG 2008 Confirms New Device Functions Like 'Rear-View Mirror' to Provide Improved View of the Colon 5Doctors Often Fail to Spot Suicidal Patients 1926 1Doctors Often Fail to Spot Suicidal Patients 1926 2Doctors Often Fail to Spot Suicidal Patients 1926 3Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 1Pelosi Slaughter and Tubbs Jones Introduce Health Tracking Legislation 1924 2USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 1USC receives 247 5M for Comprehensive Center of Excellence in Minority Health 1922 2SalesForce4Hire Opens New Office 1920 1SalesForce4Hire Opens New Office 1920 2
...wire-FirstCall/ -- Shire plc ,the market leader i...isorder (ADHD), announced that it will present key...t the American Psychiatric,Association (APA) annua..."The upcoming clinical research to be presented at... the science of ADHD treatment,",said Eliseo Salin...
...5, 2007 - Gemin X Biotechnologies,Inc. announced t...demonstrated that its lead compound, obatoclax (GX...l Lymphoma (MCL) cell lines and,primary cells from...molecule specifically designed to inhibit all rele...ted cancer target, thus restoring,the natural cell...
Other Medicine Technology:Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 2Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 3Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 4Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 5Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 6Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting 7Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 2Gemin X Biotechnologies Announces Publication in Blood of Positive,Preclinical Data of Lead Compound in Mantle Cell Lymphoma 3
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...1 or juvenile-onset diabetes also works in a rat m...g to a new report from researchers at Washington U...g that we can cure type 2 diabetes in the same way... type 2 diabetes is almost 20 times more prevalent...
...es the establishment of the Center for Celiac Dise...ose//, treat and provide support for patients and ...ac disease is unable to digest gluten, a common in...g bread, pasta and even condiments,” said Ritu Ver...
...hydrate molecules so as to prepare for an invasion...of Florida, which has been published in the curren...not only humans but viruses too that crave for car...ed that the viruses hang on to the carbohydrates t...
...f Adults Cannot Manage Without Cell Phones.The res...shire in Stoke-on-Trent, who had conducted the res...ictive behavior when it comes to their cell phones...mobile phones, he observed that some of the behavi...
Other Medicine News:Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 2Health News:Transplant Cures Rats’ Type 2 Diabetes without Need for Immune Suppression Drug 3Health News:Center for Celiac Disease Opens 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 3
Introducing the new Platinum 10 concentrator. The Platinum 10 delivers the reliability, performance and value advantage you have come to expect from the Platinum line of concentrators and provides an
...table Oxygen Concentrator is the most compact, lig...than 10 lbs (4.5 kg), this unit was designed to ac...e oxygen patient., ,Operating as a pulse flow... oxygen concentrator and an oxygen conserver in on...
OCD-3000 pnuematic conserving regulator.
...7.5 liters out of your five-liter concentrators. ,...igh-flow patients! , ,In many ways, the OXYMIZER...e standard conservers, because they extend oxygen ...o saturate a patient. However, they do not requir...
Medicine Products: